Anti-CD47 Antibody Granted Orphan Drug Designation for Multiple Myeloma

The FDA has granted Orphan Drug designation to Surface Oncology’s lead investigational candidate SRF231, a potential treatment for patients with multiple myeloma.

Source link

Related posts

A monocyte gene expression signature in the early clinical course of Parkinson’s disease.


neurosciencestuff: (Image caption: Various 3-D views of the…


What is PANDAS?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy